NCT04523688View on ClinicalTrials.gov

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
GlioblastomaVaccination
Interventions
BIOLOGICAL

Autologous Dendritic Cells (DC) vaccine

10×10exp6 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)

DRUG

Temozolomide

Adjuvant temozolomide assumed orally from day 1 to 5 (start on week 5). Dosage: 150mg/m2/day for the first cycle and 200 mg/m2/day for subsequent cycles (q28).

Trial Locations (1)

47014

RECRUITING

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER